1. Severe West Nile Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Infections in a Patient With Thymoma and Anti-Type I Interferon Antibodies.
- Author
-
Barzaghi F, Visconti C, Pipitone GB, Bondesan S, Molli G, Giannelli S, Sartirana C, Lampasona V, Bazzigaluppi E, Brigatti C, Gervais A, Bastard P, Tassan Din C, Molinari C, Piemonti L, Casanova JL, Carrera P, Casari G, and Aiuti A
- Subjects
- Humans, Male, Middle Aged, Thymus Neoplasms immunology, Thymus Neoplasms complications, Toll-Like Receptor 3 genetics, Toll-Like Receptor 3 immunology, Thymoma immunology, Thymoma complications, West Nile Fever immunology, West Nile Fever complications, COVID-19 immunology, COVID-19 complications, COVID-19 diagnosis, SARS-CoV-2 immunology, Autoantibodies blood, Autoantibodies immunology, Interferon Type I immunology, West Nile virus immunology
- Abstract
Patients with severe West Nile virus and SARS-CoV-2 infections deserve accurate diagnosis of underlying diseases, determining possible anti-interferon autoantibody production, since they must receive antiviral and immunological therapies to enhance antiviral response. The current study aimed to investigate determinants of severity in a previously healthy patient who experienced 2 life-threatening infections, from West Nile Virus (WNV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). During coronavirus disease 2019 (COVID-19) hospitalization he was diagnosed with a thymoma, retrospectively identified as already present at the time of WNV infection. Heterozygosity for p.Pro554Ser in the TLR3 gene, which increases susceptibility to severe COVID-19, and homozygosity for CCR5 c.554_585del, associated with severe WNV infection, were found. Neutralizing anti-interferon (IFN)-α and anti-IFN-ω autoantibodies were detected, likely induced by the underlying thymoma and increasing susceptibility to both severe COVID-19 pneumonia and West Nile encephalitis., Competing Interests: Potential conflicts of interest. J.-L. C. is an inventor on patent application PCT/US2021/042741, filed 22 July 2021, submitted by The Rockefeller University and covering the diagnosis of susceptibility to, and the treatment of, viral disease, and viral vaccines, including COVID-19 and vaccine-associated diseases. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2025
- Full Text
- View/download PDF